Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Ebina, Yasuhiko; Mikami, Mikio; Nagase, Satoru; Tabata, Tsutomu; Kaneuchi, Masanori; Tashiro, Hironori; Mandai, Masaki; Enomoto, Takayuki; Kobayashi, Yoichi; Katabuchi, Hidetaka; Yaegashi, Nobuo; Udagawa, Yasuhiro; Aoki, Daisuke

doi:10.1007/s10147-018-1351-y

Cited by 115 publications

(140 citation statements)

References 49 publications

Supporting

Mentioning

138

Contrasting

Order By: Relevance

“…The current primary treatment for cervical cancer is surgery, radiotherapy and chemotherapy (8). Although improvements have been made, there remain limitations associated with the current treatment options (9). Recurrent cervical cancer and metastasis occur frequently in patients with advanced cervical cancer (10).…”

Section: Introductionmentioning

confidence: 99%

Downregulation of microRNA‑425‑5p suppresses cervical cancer tumorigenesis by targeting AIFM1

Zhang¹,

Yang²,

Liu³

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Although microRNA-425-5p (miR-425-5p) has been previously revealed to be upregulated in cervical cancer, the cellular function of miR-425-5p in cervical cancer remains unknown. The aim of the current study was to investigate the cellular function of miR-425-5p and its underlying mechanism in cervical cancer. Reverse transcription-quantitative polymerase chain reaction was used to measure miR-425-5p expression in several cervical cancer cell lines. TargetScan bioinformatics analysis was used to predict apoptosis-inducing factor mitochondria-associated 1 (AIFM1) as a novel target of miR-425-5p, and this was verified by dual-luciferase reporter assay. Furthermore, cell transfections were used to investigate the role of miR-425-5p in cervical cancer. The effect of miR-425-5p on cell viability and apoptosis in HeLa cells was detected by MTT assay and flow cytometry, respectively. The present study demonstrated that miR-425-5p was significantly upregulated in cervical cancer cell lines. In addition, AIFM1 was identified as a direct target of miR-425-5p and negatively regulated by miR-425-5p. Downregulation of miR-425-5p inhibited HeLa cell viability and induced cell apoptosis. Furthermore, downregulation of miR-425-5p significantly increased the protein and mRNA expression levels of cytochrome c, caspase-3, caspase-9 and DNA damage regulated autophagy modulator 1. The effects of miR-425-5p inhibition on HeLa cell viability and apoptosis were significantly reversed by AIFM1 knockdown. In conclusion, the present study demonstrated that miR-425-5p was upregulated in cervical cancer, and downregulation of miR-425-5p inhibited cervical cancer cell growth by targeting AIFM1.

show abstract

Section: Introductionmentioning

confidence: 99%

Downregulation of microRNA‑425‑5p suppresses cervical cancer tumorigenesis by targeting AIFM1

Zhang¹,

Yang²,

Liu³

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Current guidelines from multiple organizations do not recommend peritoneal cytology evaluation as a standard practice [2,38]. Based on our results and others, it may be useful to integrate peritoneal cytology testing as a routine surgical procedure at the time of radical hysterectomy for early-stage cervical cancer, as it appears that malignant peritoneal cytology can potentially impact survival.…”

Section: Clinical Implicationmentioning

confidence: 87%

Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study

Matsuo

Shimada

Matsuzaki

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

This study examined the association between peritoneal cytology and survival in early-stage cervical cancer. This is a nationwide multicenter retrospective study, examining consecutive women with clinical stage IB1-IIB cervical cancer who underwent radical hysterectomy with available peritoneal cytology results from 2004–2008. Propensity score inverse probability of treatment weighting was used to assess the impact of malignant peritoneal cytology on survival. Among 1409 analyzed cases, 88 (6.2%) had malignant peritoneal cytology. On weighted models, malignant peritoneal cytology was associated with decreased disease-free survival (hazard ratio (HR) 1.78, 95% confidence interval (CI) 1.36–2.32) and overall survival (OS, HR 1.93, 95% CI 1.44–2.59). On sensitivity analyses, malignant peritoneal cytology was associated with decreased OS in adenocarcinoma/adenosquamous carcinoma, high-risk early-stage disease and those who received concurrent chemo-radiotherapy. However, among women who received postoperative systemic chemotherapy, malignant peritoneal cytology was not associated with OS (HR 1.21, 95% CI 0.72–2.04). A systematic review, including our results, showed that malignant peritoneal cytology was associated with decreased OS (HR 4.03, 95% CI 1.81–8.99) and increased recurrence in squamous carcinoma (odds ratio 1.89, 95% CI 1.05–3.39) and adenocarcinoma (odds ratio 4.30, 95% CI 2.30–8.02). In conclusion, the presence of malignant cells in peritoneal cytology is associated with decreased survival in early-stage cervical cancer. The possible benefit of systemic chemotherapy in this subgroup merits further investigation.

show abstract

“…All patients underwent a review of their medical history and lifestyle habits (smoking-positive: Current smokers of ≥10 cigarettes/day; alcohol intake-positive: Alcohol intake of ≥14 g/day), physical examination and routine clinical staging. The patients were treated according to the Japan Society of Gynecologic Oncology clinical The presence of chronic diseases contributes to the occurrence risk factors for gynecological cancers in Japan guidelines (14)(15)(16). The treatment options for gynecological cancer included surgery, radiotherapy and/or chemotherapy, depending on tumor stage and additional risk factors.…”

Section: Methodsmentioning

confidence: 99%

The presence of chronic diseases contributes to the occurrence risk factors for gynecological cancers in Japan

et al. 2020

View full text Add to dashboard Cite

The aim of the present study was to determine whether chronic diseases (CD), such as hypertension, diabetes mellitus, dyslipidemia, heart diseases and cerebrovascular diseases, are occurrence risk factors and affect the survival of patients with gynecological cancers (GC). The correlations between CD and the characteristics and survival of 1,590 GC patients [685 with cervical cancer (CC), 613 with endometrial cancer (EM) and 292 with ovarian cancer (OV)] were investigated in the present study. Of the CD patients, 189 had CC (27.6%), 265 had EM (43.2%) and 72 had OV (24.7%). The incidence of CD increased with age in GC patients. The number of CD patients aged ≥70 years, was 8.6-fold higher in the CC group, 3.0-fold higher in the EM group, and 9.6-fold higher in the OV group compared with those aged <50 years. CD and excess body weight were associated with GC regardless of patient age. However, there was no correlation between CD and survival at any age in GC patients. These findings indicate that CD contribute to >24% of the occurrence risk factors in GC patients in Japan.

show abstract

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Cited by 115 publications

References 49 publications

Downregulation of microRNA‑425‑5p suppresses cervical cancer tumorigenesis by targeting AIFM1

Downregulation of microRNA‑425‑5p suppresses cervical cancer tumorigenesis by targeting AIFM1

Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study

The presence of chronic diseases contributes to the occurrence risk factors for gynecological cancers in Japan

Contact Info

Product

Resources

About